News
-
-
PRESS RELEASE
Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan
Intellipharmaceutics International Inc. announces listing transfer from TSX to NEX due to Cease Trade Order, new stock option plan approved. Company specializes in controlled-release drugs -
-
-
-
PRESS RELEASE
Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form
Intellipharmaceutics International Inc. announces delay in filing annual audited financial statements for the fiscal year ended November 30, 2023, due to applicable Canadian securities laws. Company working to expedite filing for compliance with OSC regulations -
PRESS RELEASE
Intellipharmaceutics International Inc. Announces Stock Option Grant
Intellipharmaceutics International Inc. issued 1,910,000 common share purchase options to certain eligible individuals under the stock option plan. The options vest over a period of 2 years and expire on February 5, 2034 -
PRESS RELEASE
Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange
Intellipharmaceutics International Inc., a pharmaceutical company, has received conditional approval to list its common shares on the TSX Venture Exchange as a Tier 2 Life Science Issuer. The company's management is working to meet the listing conditions, with expectations for a seamless transition from the Toronto Stock Exchange. Intellipharmaceutics specializes in the research, development, and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix ™ technology offers a multidimensional controlled-release drug delivery platform with various product candidates in the development pipeline. The company has also issued cautionary statements regarding forward-looking information. For further details, refer to the press release. -
-
PRESS RELEASE
Intellipharmaceutics Reports Director Election Results
-
LaMar’s Donuts Celebrates National Donut Day 2024
-
abrdn U.S. Closed-End Funds Announce Distribution Payment Details
-
abrdn Income Credit Strategies Fund Announces Update and Tentative Closing Date for Acquisition of Assets From First Trust High Income Long/Short Fund
-
Electric Royalties Announces Interest Conversion Under Convertible Credit Facility
-
Pfister Faucets' American Plumber Stories Docuseries Wins Three Telly Awards
-
EQS-Adhoc: Vectron Systems AG: Vectron enters into Business Combination Agreement, resolves 10% capital increase without subscription rights of the shareholders and supports voluntary public acqusition offer
-
CPI PROPERTY GROUP publishes financial results for the first quarter of 2024
-
Leclanché SA: Publishes its Annual Report 2023 and Non-financial ESG Report
-
Spexis receives second extension for the publication of its 2023 annual report until July 31, 2024, releasing its unaudited financial statements and providing an update on its dispute with SPRIM.
-
Molten Ventures Plc: HOL-Holding(s) in Company
-
ACCOR - Description of own share buyback programme
-
ACCOR - Press release following the 2024 general meeting
-
Capital increase through exercise of subscription rights
-
NFL BIOSCIENCES: RESULTS OF THE COMBINED GENERAL MEETING OF MAY 30, 2024
-
Thales has completed the sale of its Ground Transportation Systems business